Abiopharma

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

UTHR: Notification

UTHR: Notification

Nuwellis Announces Changes to Board of Directors

New Form 424B5 - SOLIGENIX, INC. Filed: 2026-01-23 AccNo: 0001104659-26-006255 Size: 480 KB

New Form 3 - UNITED THERAPEUTICS Corp Filed: 2026-01-23 AccNo: 0002107022-26-000003 Size: 3 KB

New Form 8-K/A - BIOCRYST PHARMACEUTICALS INC Filed: 2026-01-23 AccNo: 0001171843-26-000405 Size: 189 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spyre Therapeutics Announces Grants of Inducement Awards